

# Rozbeh Jafari

## List of Publications by Year in Descending Order

**Source:** <https://exaly.com/author-pdf/4021992/rozbeh-jafari-publications-by-year.pdf>

**Version:** 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

17  
papers

2,324  
citations

8  
h-index

22  
g-index

22  
ext. papers

2,948  
ext. citations

10.8  
avg, IF

4.38  
L-index

#	Paper	IF	Citations
17	Integrative multi-omics and drug response profiling of childhood acute lymphoblastic leukemia cell lines.. <i>Nature Communications</i> , <b>2022</b> , 13, 1691	17.4	0
16	Inhibition of the ubiquitin-proteasome system by an NQO1-activatable compound. <i>Cell Death and Disease</i> , <b>2021</b> , 12, 914	9.8	
15	Thermal proteome profiling identifies PIP4K2A and ZADH2 as off-targets of Polo-like kinase 1 inhibitor volasertib. <i>FASEB Journal</i> , <b>2021</b> , 35, e21741	0.9	0
14	The transcriptome-wide landscape of molecular subtype-specific mRNA expression profiles in acute myeloid leukemia. <i>American Journal of Hematology</i> , <b>2021</b> , 96, 580-588	7.1	2
13	Novel Broad-Spectrum Antiviral Inhibitors Targeting Host Factors Essential for Replication of Pathogenic RNA Viruses. <i>Viruses</i> , <b>2020</b> , 12,	6.2	9
12	Proteogenomic Subtyping of Chronic Lymphocytic Leukemia Identifies a Novel Poor Outcome Subgroup with a Distinct Drug Response Profile. <i>Blood</i> , <b>2020</b> , 136, 10-11	2.2	
11	Proteogenomics and Hi-C reveal transcriptional dysregulation in high hyperdiploid childhood acute lymphoblastic leukemia. <i>Nature Communications</i> , <b>2019</b> , 10, 1519	17.4	31
10	Validation and development of MTH1 inhibitors for treatment of cancer. <i>Annals of Oncology</i> , <b>2016</b> , 27, 2275-2283	10.3	77
9	CETSA screening identifies known and novel thymidylate synthase inhibitors and slow intracellular activation of 5-fluorouracil. <i>Nature Communications</i> , <b>2016</b> , 7, 11040	17.4	96
8	The cellular thermal shift assay for evaluating drug target interactions in cells. <i>Nature Protocols</i> , <b>2014</b> , 9, 2100-22	18.8	559
7	Tracking cancer drugs in living cells by thermal profiling of the proteome. <i>Science</i> , <b>2014</b> , 346, 1255784	33.3	526
6	Monitoring drug target engagement in cells and tissues using the cellular thermal shift assay. <i>Science</i> , <b>2013</b> , 341, 84-7	33.3	982
5	Construction of divalent anti-keratin 8 single-chain antibodies (sc(Fv)(2)), expression in <i>Pichia pastoris</i> and their reactivity with multicellular tumor spheroids. <i>Journal of Immunological Methods</i> , <b>2011</b> , 364, 65-76	2.5	7
4	Optimization of production of the anti-keratin 8 single-chain Fv TS1-218 in <i>Pichia pastoris</i> using design of experiments. <i>Microbial Cell Factories</i> , <b>2011</b> , 10, 34	6.4	26
3	Functional mapping of the anti-idiotypic antibody anti-TS1 scFv using site-directed mutagenesis and kinetic analysis. <i>MABs</i> , <b>2010</b> , 2, 662-9	6.6	
2	Localization of complexed anticytokeratin 8 scFv TS1-218 to HeLa HEP-2 multicellular tumor spheroids and experimental tumors. <i>Cancer Biotherapy and Radiopharmaceuticals</i> , <b>2010</b> , 25, 455-63	3.9	4
1	Functional mapping and single chain construction of the anti-cytokeratin 8 monoclonal antibody TS1. <i>Molecular Immunology</i> , <b>2007</b> , 44, 1075-84	4.3	5

